Randomized trials in the first-line, second-line, and third-line colorectal/ platinum-resistant ovarian cancer settings7,20–24,31 show that the addition of VEGF pathway inhibitors to cytotoxic therapy improves PFS1. The gene discussed is VEGFA; the disease is ovarian cancer.